Woman sitting on a beach

Our goals are big.
Our mission is powerful.

Photo of a nurse

We exist to help women living with cancer reclaim their health, their strength and their lives.

At Olema Oncology we leverage our deep understanding of endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies. Our current focus is OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is currently being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. We have aspirations to develop OP-1250 in a number of other ER+ breast cancer indications, both as a monotherapy and in combination with approved therapies that have shown synergistic effects with other endocrine therapies.

Join us as we aim to design therapies for improving lives.

Press Releases

Board of Directors

Ian Clark,

Chairperson of the Board

Sean P. Bohen, M.D., Ph.D.

President and Chief Executive Officer

Cynthia M. Butitta

Frank McCormick, Ph.D., FRS, D.Sc (Hon)

Andy Rappaport

Gorjan Hrustanovic, Ph.D.

Graham Walmsley, M.D., Ph.D.

Cyrus Harmon, Ph.D.

Our Investors

BVF Partners Logo
Logos Capital Logo
Janus Henderson Logo
Cormorant Asset Management Logo
Wellington Management Logo
RA Capital Logo
Vivo Logo
Venrock Logo
Surveyor Logo
Deerfield Logo
Foresite Capital Logo
OrbiMed Capital Logo